|Bid||5.02 x 3200|
|Ask||5.15 x 800|
|Day's Range||4.97 - 5.15|
|52 Week Range||3.64 - 6.30|
|Beta (3Y Monthly)||2.16|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 8, 2018 - May 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.20|
Inovio Pharmaceuticals, Inc. (INO) made strategic leadership appointments in preparation for the commercialization of its lead asset and further development of its pipeline of immunotherapies and vaccines for cancer and challenging infectious diseases.
Inovio (INO) delivered earnings and revenue surprises of 15.63% and -9.05%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Plymouth Meeting, Pennsylvania-based company said it had a loss of 27 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by ...
PLYMOUTH MEETING, Pa., Nov. 08, 2018 -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), a late-stage biotechnology company focused on the development and commercialization of DNA.
Inovio Pharmaceuticals Inc (NASDAQ:INO), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is INO Read More...
PLYMOUTH MEETING, Pa., Nov. 05, 2018 -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that the Company will participate in the following upcoming investment.
PLYMOUTH MEETING, Pa., Oct. 25, 2018 -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its synthetic HIV vaccine PENNVAX®-GP delivered via intradermal route.
Inovio Pharmaceuticals, Inc. (INO) announced today that it will host a conference call and live webcast to report its 2018 third quarter financial results on Thursday, November 8, 2018 at 4:30 p.m. ET. Inovio is a late-stage biotechnology company focused on the discovery, development, and commercialization of DNA immunotherapies that transform the treatment of cancer and infectious diseases. Inovio’s proprietary platform technology applies next-generation antigen sequencing and DNA delivery to activate potent immune responses to targeted diseases.
Inovio Pharmaceuticals, Inc. (INO) today announced that new data from the company’s recently completed Phase 1b study with INO-5150 demonstrated a slowing of Prostate-Specific Antigen Doubling Time (PSADT) in men with prostate cancer. In this study, Inovio evaluated the tolerability and immunogenicity of INO-5150, a DNA vaccine encoding PSA and PSMA, with or without INO-9012 (encoding IL-12 immune adjuvant), in men with biochemically relapsed prostate cancer.
Inovio Pharmaceuticals, Inc. (INO) announced today that it has received the first two U.S. patents for its DNA-encoded monoclonal antibody technology (dMAb™) from the U.S. Patent & Trademark Office and has been awarded a $2.2 million grant from the Bill & Melinda Gates Foundation to advance its dMAb platform and new clinical delivery devices. This U.S. patent protection of Inovio’s dMAb intellectual property will provide exclusivity for the use of this innovative technology.
Inovio Pharmaceuticals, Inc. (INO) announced today that its Ebola vaccine (INO-4212) provided 100% protection following a challenge with a lethal dose of the Ebola virus in a preclinical study. Scientists observed that vaccination induced long-term immune responses in monkeys that were detectable for at least one year after the final vaccination. Laurent Humeau, Ph.D., Inovio’s Senior Vice President R&D, said, “Unlike all other Ebola vaccine candidates in development, INO-4212 is a vaccine that has shown to be stable at room temperature for one year.
NEW YORK, Oct. 09, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Inovio Pharmaceuticals, Inc. (INO) announced today the successful animal testing of DNA-encoded monoclonal antibodies targeting the immune checkpoint molecule CTLA-4 as published in Cancer Research. More importantly, Inovio’s dMAb constructs for anti-human CTLA-4 antibodies ipilimumab (YERVOY®) and tremelimumab, achieved high expression levels in mice (approximately 85µg/ml and 58µg/ml, respectively). This research publication is significant because it is the first to report on the use of Inovio dMAb technology to develop novel monoclonal antibody-based therapies targeting checkpoint inhibitors.
Vaxart's (VXRT) oral flu vaccine candidate achieves 39% reduction in flu illness compared to 27% for market leader, Sanofi's Fluzone.
NEW YORK, NY / ACCESSWIRE / October 3, 2018 / Inovio Pharmaceuticals saw its shares climb over 14% by the close on Tuesday as traders digested positive data that was published in Clinical Cancer Research. ...
Inovio Pharmaceuticals, Inc. (INO) announced today a paper published in a major cancer journal detailed results of a patient with head and neck cancer treated with MEDI0457 achieved a sustained complete response (full remission) on treatment with a subsequent PD-1 checkpoint inhibitor. In the Inovio-sponsored study of 22 patients with head and neck squamous cell carcinoma the company reported 91% (20/22) showed T cell activity in the blood or tissue. MEDI0457 – formerly called INO-3112 – was in 2015 licensed to MedImmune, the global biologics research and development arm of AstraZeneca. Dr. J. Joseph Kim, Inovio's President and CEO, said, "We are buoyed by the study as it lends support to all of our HPV and oncology programs.
After ending almost flat in the week ended Sept. 14, biotech stocks have seen some bounce in the running week, with the iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) up about 1.3 percent through Thursday. ...
HENDERSON, NV / ACCESSWIRE / September 18, 2018 / We have discovered a very interesting biotechnology company ENDV (Endonovo Therapeutics, Inc.), has an FDA cleared product, and is flying under the radar. ...
Inovio Pharmaceuticals, Inc. (INO) announced today that its SynCon® vaccine approach using a collection of DNA antigens generated broadly protective antibody responses against the most deadly strains of the H3N2 influenza viruses from the past 50 years and provided complete protection against heterologous lethal challenge in a preclinical study. Study results were published online in the journal, Human Gene Therapy, in an article by Inovio and its collaborators entitled, “A Synthetic Micro-Consensus DNA Vaccine Generates Comprehensive Influenza-A H3N2 Immunity and Protects Mice Against Lethal Challenge by Multiple H3N2 Viruses.” This work was supported by a grant from the U.S. National Institutes of Health.
Biotech were trending mostly sideways in the week ending Sept. 14 after posting weekly gains in the previous two weeks. Notwithstanding the overall muted sentiment, there was some activity in reaction ...